Publication details
Pegaptanib (Macugen) 1,5 leté výsledky terapie vlhké formy VPMD
| Title in English | Pegaptanib (Macugen) 1.5 year results of treatment of wet AMD |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The authors evaluated results achieved with the use of pegaptanib (Macugen) for wet age-related macular degeneration (AMD). Pegaptanib (Macugen, Pfizer) is the first antagonist of the vascular growth factor (VEGF), approved for intraocular injection in the wet form of age-related macular degeneration (AMD). Pegaptanib is used in our department to treat patients with occult or minimally classic subretinal neovascular membrane (CNV) in the subfoveal location. The group included 134 patients with occult, minimally classic and classic CNV in wet AMD (48 women, 86 men). The mean age of patients in the group is 73.2 years. |